cells transplantation
Contributions
Type: Publication Only
Background
Modern chemotherapy schemes of acute myeloid leukemia include remission of induction regimens with escalated doses of anthracyclines (escalated “7+3” regimen). Changes in incidence of febrile neutropenia are not clear in patients receiving remission induction regimen “7+3” with escalated anthracycline dose ( 90mg?m2 ) comparing to standart “7+3” chemotherapy regimen( 45mg? m2 ).
Aims
The aim of the study was to assess the influence of “7+3” chemotherapy regimen with escalated anthracyclines on incidence of febrile neutropenia in patients with acute myeloid leukemia comparing to standard “7+3” chemotherapy regimen.
Methods
56 hospitalization episodes of patients with acute myeloid leukemia on chemotherapy from March 2013 to January 2014 were reviewed. Incidence of febrile neutropenia (fulfilled criteria of Freifeld et al., 2011) was compared in the groups receiving standard “7+3” regimen and “7+3” with escalated anthracyclines. Groups were comparable by age and gender characteristics and adjusted for other possible confounders.
Results
No statistically significant difference in incidence of neutropenia in patients receiving the escalated “7+3” regimen comparing to the standard one was found (71% to 70% accordingly, p=1, exact Fisher’s criterion).
Summary
Use of “7+3” chemotherapy regimen with escalated anthracycline dose in treatment of acute myeloid leukemia does not increase the risk for development of febrile neutropenia in patients.
Session topic: Publication Only
Type: Publication Only
Background
Modern chemotherapy schemes of acute myeloid leukemia include remission of induction regimens with escalated doses of anthracyclines (escalated “7+3” regimen). Changes in incidence of febrile neutropenia are not clear in patients receiving remission induction regimen “7+3” with escalated anthracycline dose ( 90mg?m2 ) comparing to standart “7+3” chemotherapy regimen( 45mg? m2 ).
Aims
The aim of the study was to assess the influence of “7+3” chemotherapy regimen with escalated anthracyclines on incidence of febrile neutropenia in patients with acute myeloid leukemia comparing to standard “7+3” chemotherapy regimen.
Methods
56 hospitalization episodes of patients with acute myeloid leukemia on chemotherapy from March 2013 to January 2014 were reviewed. Incidence of febrile neutropenia (fulfilled criteria of Freifeld et al., 2011) was compared in the groups receiving standard “7+3” regimen and “7+3” with escalated anthracyclines. Groups were comparable by age and gender characteristics and adjusted for other possible confounders.
Results
No statistically significant difference in incidence of neutropenia in patients receiving the escalated “7+3” regimen comparing to the standard one was found (71% to 70% accordingly, p=1, exact Fisher’s criterion).
Summary
Use of “7+3” chemotherapy regimen with escalated anthracycline dose in treatment of acute myeloid leukemia does not increase the risk for development of febrile neutropenia in patients.
Session topic: Publication Only